ArticleInfection and immunity2009
Paracoccidioides brasiliensis vaccine formulations based on the gp43-derived P10 sequence and the Salmonella enterica FliC flagellin.
Article in Infection and immunity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 53 citations in OpenAlex.
- Immunity to fungi and vaccine considerations.Cell host & microbe · 2024Review
- Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi.Archives of microbiology · 2024Review
- The story of Paracoccidiodes gp43.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Review
- Fungal Vaccine Development: State of the Art and Perspectives Using Immunoinformatics.Journal of fungi (Basel, Switzerland) · 2023Review
- Targeting the P10 Peptide in Maturing Dendritic Cells via the DEC205 Receptor In Vivo: A New Therapeutic Strategy against Paracoccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2023Article
- Antibodies to Combat Fungal Infections: Development Strategies and Progress.Microorganisms · 2023Review
- Application of anti-fungal vaccines as a tool against emerging anti-fungal resistance.Frontiers in fungal biology · 2023Review
- Recombinant AttenuatedCancers · 2022Review
- Neutrophil Cells Are Essential for The Efficacy of a Therapeutic Vaccine against Paracoccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2021Article
- Interactions of Extracellular Vesicles from Pathogenic Fungi with Innate Leukocytes.Current topics in microbiology and immunology · 2021Article
- Article
- Recombinant vaccines of a CD4+ T-cell epitope promote efficient control of Paracoccidioides brasiliensis burden by restraining primary organ infection.PLoS neglected tropical diseases · 2017Article
- Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10.Immunology and cell biology · 2015Article
- Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.Human vaccines & immunotherapeutics · 2014Review
- Universal fungal vaccines: could there be light at the end of the tunnel?Human vaccines & immunotherapeutics · 2012Review
- Paracoccidioidomycosis vaccine.Human vaccines & immunotherapeutics · 2012Review
- Therapeutic DNA vaccine encoding peptide P10 against experimental paracoccidioidomycosis.PLoS neglected tropical diseases · 2012Article
- New advances in the development of a vaccine against paracoccidioidomycosis.Frontiers in microbiology · 2012Article
- The role of adjuvants in therapeutic protection against paracoccidioidomycosis after immunization with the P10 peptide.Frontiers in microbiology · 2012Article
- A TCR transgenic mouse reactive with multiple systemic dimorphic fungi.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paracoccidioidomycosis (PCM) is a systemic granulomatous disease caused by the dimorphic fungus Paracoccidioides brasiliensis. Anti-PCM vaccine formulations based on the secreted fungal cell wall protein (gp43) or the derived P10 sequence containing a CD4(+) T-cell-specific epitope have shown promising results. In the present study, we evaluated new anti-PCM vaccine formulations based on the intranasal administration of P. brasiliensis gp43 or the P10 peptide in combination with the Salmonella enterica FliC flagellin, an innate immunity agonist binding specifically to the Toll-like receptor 5, in a murine model. BALB/c mice immunized with gp43 developed high-specific-serum immunoglobulin G1 responses and enhanced interleukin-4 (IL-4) and IL-10 levels. On the other hand, mice immunized with recombinant purified flagellins genetically fused with P10 at the central hypervariable domain, either flanked or not by two lysine residues, or the synthetic P10 peptide admixed with purified FliC elicited a prevailing Th1-type immune response based on lung cell-secreted type 1 cytokines. Mice immunized with gp43 and FliC and intratracheally challenged with P. brasiliensis yeast cells had increased fungal proliferation and lung tissue damage. In contrast, mice immunized with the chimeric flagellins and particularly those immunized with P10 admixed with FliC reduced P. brasiliensis growth and lung damage. Altogether, these results indicate that S. enterica FliC flagellin modulates the immune response to P. brasiliensis P10 antigen and represents a promising alternative for the generation of anti-PCM vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.